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Background: The construction of plasmid vectors for transgene expression in the malaria parasite, Plasmodium
falciparum, presents major technical hurdles. Traditional molecular cloning by restriction and ligation often yields
deletions and re-arrangements when assembling low-complexity (A + T)-rich parasite DNA. Furthermore, the use of
large 5′- and 3′- untranslated regions of DNA sequence (UTRs) to drive transgene transcription limits the number of
expression cassettes that can be incorporated into plasmid vectors.
Methods: To address these challenges, two high fidelity cloning strategies, namely yeast homologous
recombination and the Gibson assembly method, were evaluated for constructing P. falciparum vectors.
Additionally, some general rules for reliably using the viral 2A-like peptide to express multiple proteins from a single
expression cassette while preserving their proper trafficking to various subcellular compartments were assessed.
Results: Yeast homologous recombination and Gibson assembly were found to be effective strategies for
successfully constructing P. falciparum plasmid vectors. Using these cloning methods, a validated family of
expression vectors that provide a flexible starting point for user-specific applications was created. These vectors are
also compatible with traditional cloning by restriction and ligation, and contain useful combinations of commonly
used features for enhancing plasmid segregation and site-specific integration in P. falciparum. Additionally,
application of a 2A-like peptide for the synthesis of multiple proteins from a single expression cassette, and some
rules for combinatorially directing proteins to discrete subcellular compartments were established.
Conclusions: A set of freely available, sequence-verified and functionally validated parts that offer greater flexibility
for constructing P. falciparum vectors having expanded expression capacity is provided.Background
Malaria continues to be a leading cause of morbidity and
mortality worldwide. Nearly 50% of the global popula-
tion is at risk, and in 2010 there were an estimated 219
million cases and 660,000 deaths [1]. Plasmodium falcip-
arum is the parasite pathogen responsible for the most
virulent disease. No vaccine is clinically approved to pre-
vent malaria. Treatment relies heavily on the use of a
limited number of anti-malarial drugs to which resist-
ance is increasingly widespread [2], which makes it* Correspondence: jcniles@mit.edu
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reproduction in any medium, provided the orcritical to identify new and effective drugs. Using genetic
approaches to validate potential drug targets in P. falcip-
arum is pivotal to this effort. However, the process of
constructing the plasmid vectors needed for these stud-
ies is time-consuming and inefficient, and imposes a sig-
nificant barrier to genetically manipulating the parasite.
Several aspects of parasite biology interact to create
this challenge. First, the parasite’s genome is extremely
(A + T)-rich (80-90%) [3], and extended regions of low
complexity sequence are common [4,5]. Second, regula-
tory 5' and 3' UTR sequences are poorly defined in
P. falciparum, and large regions of putative regulatory
DNA are needed to facilitate robust transgene expres-
sion [6]. Very few 5′ and 3′ UTRs have been precisely
mapped. As a result, 1-2 kb 5′ and 3′ UTRs arel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Wagner et al. Malaria Journal 2013, 12:373 Page 2 of 13
http://www.malariajournal.com/content/12/1/373frequently selected on the assumption that these com-
prise the information necessary to support efficient tran-
scription [6-9]. These long UTRs are close to 90% in
(A + T) composition. Third, the mean coding sequence
(CDS) length in P. falciparum (excluding introns) is
2.3 kb, nearly twice that of many model organisms [3].
Gene complementation is a powerful strategy, used ex-
tensively in forward genetics studies in other organisms,
but this approach is under-utilized in P. falciparum due
in large part to the challenges associated with efficiently
assembling the necessary complementing constructs
[10]. The ability to more routinely construct expression
vectors for complementation studies is highly synergistic
with the increasing rate at which genome-wide inser-
tional mutagenesis studies are identifying candidate
genes associated with growth, cell cycle and other
phenotypic defects in P. falciparum [11,12]. In con-
structing over-expression, complementation and gene
targeting vectors in P. falciparum, long (A + T)-rich re-
gions must be cloned into final plasmids that can exceed
10 kb. It is recognized that the traditional and com-
monly used restriction/ligation-based cloning method is
inefficient for assembling these vectors, and often yields
plasmids with regions that are deleted and/or re-
arranged [13]. Consequently, time-consuming screening
of large numbers of bacterial clones is needed to in-
crease the probability of recovering the intact target vec-
tor, if it is at all present.
In addition to the vector assembly challenges, typical
over-expression vectors are limited in the number of
transgenes that can be simultaneously expressed. In the
most common format, two expression cassettes are
available, and one of these is dedicated to expressing a
selectable marker [7]. Increasing the expression capacity
of a single plasmid can be accomplished by introducing
additional 5'UTR-CDS-3'UTR cassettes, but this further
complicates vector construction for reasons described
above. This problem has been circumvented in several
eukaryotes through the use of a viral 2A-like peptide
that prevents peptide bond formation between two spe-
cific and adjacent amino acids during translation and re-
sults in the production of two separate proteins from a
single expression cassette [14]. Recently, the 2A signal
has been shown to be functional in P. falciparum [15],
but its broader utility with respect to proteins that are
trafficked to different subcellular parasite compartments
has not been examined.
Here, an inexpensive and straightforward strategy for
more robustly and flexibly assembling P. falciparum vec-
tors is introduced, while simultaneously maximizing the
amount of transgenic information expressible from a
single plasmid without using additional 5′UTR-CDS-3′
UTR expression cassettes. This has been achieved by de-
veloping a family of vectors that integrate use of highfidelity and robust DNA assembly by yeast homologous
recombination [16] and in vitro assembly by the isother-
mal chew-back-anneal Gibson method [17] with trad-
itional restriction/ligation-based cloning. Additionally,
several desirable utility features have been consolidated
in this vector family, including: site-specific integration
mediated by the Bxb1 integrase [18]; improved plasmid
segregation mediated by either Rep20 elements [19] or a
P. falciparum mini-centromere (pfcen5-1.5) [20]; and all
of the currently used P. falciparum selection markers.
Lastly, the broader utility of a viral 2A-like peptide to
achieve expression from a single cassette of multiple
genes targeted to distinct parasite subcellular compart-
ments has been demonstrated. This resource is freely
available through the Malaria Research and Reference
Reagent Resource Center (MR4) [21].
Methods
Molecular biology
Unless otherwise indicated, enzymes were from New
England Biolabs (Ipswich, MA, USA) and chemicals
were from Sigma-Aldrich (St. Louis, MO, USA) or Re-
search Products International (Mt. Prospect, IL, USA).
High fidelity (HF) restriction enzymes were used when
available. PCR was routinely performed with Phusion
DNA polymerase in HF Buffer, or with a 15:1 (v:v) mix-
ture of Hemo KlenTaq:Pfu Turbo (Agilent, Santa Clara,
CA, USA) in Hemo KlenTaq Buffer. The latter condi-
tions permit PCR amplification directly from parasite
culture samples, usually included at 5% of the total reac-
tion volume. Plasmids were prepared for transfection
with maxi columns (Epoch Life Science, Missouri City,
TX, USA) or the Xtra Midi Kit (Clontech, Mountain
View, CA, USA).
Vector construction
The primers used for these studies are listed in Additional
file 1.
Yeast homologous recombination
Yeast homologous recombination (HR) vector construc-
tion was carried out by standard methods [16,22]. Vari-
able amounts of vector backbone (typically 0.1-2 μg)
were digested using standard methods to generate line-
arized vector. PCR was carried out using standard tech-
niques to generate fragments for insertion bearing 20-40
bp homology to the desired flanking regions on the vec-
tor. Competent Saccharomyces cerevisiae W303-1B was
prepared as described [23] and frozen at -80°C. Either
unpurified or column-purified PCR product was co-
transformed with either unpurified or column-purified
linearized vector. A wide range of concentrations of both
linearized vector and PCR product were observed to be
efficacious. Transformed yeast were plated on YPD agar
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20 g/L agar) supplemented with 400 mg/L G-418 disul-
phate and allowed to grow for 48-72 hours at 30°C.
Typical yields were 10-100 colonies for a negative con-
trol transformation lacking PCR insert, and 50-1,000 col-
onies for the complete HR reaction.
Colonies were then either harvested by plate scraping
or picked and grown overnight in YPD + 400 μg/mL
G-418. Cells were then treated with 2 U zymolyase
(Zymo Research, Irvine, CA, USA) in 250 μL buffer ZB
(10 mM sodium citrate pH 6.5, 1 M sorbitol, 25 mM
EDTA and 40 mM dithiothreitol) for 1 hour at 37°C to
generate spheroplasts. Yeast spheroplasts were lysed
with the addition of 250 μL buffer MX2 (0.2 M NaOH
and 10 g/L sodium dodecyl sulphate). Plasmid DNA was
then purified either by spin column (Epoch Life Science,
Missouri City, TX, USA) or alcohol precipitation.
The recovered DNA was transformed directly into
Escherichia coli DH5α or EPI300 (Epicentre Biotech-
nologies, Madison, WI, USA) prepared with a Z-
Competent Transformation Kit (Zymo Research) or
transformed by electroporation. Occasionally, the DNA
mixture was drop dialyzed against water for 20 min
prior to transformation to increase electroporation.
Plasmid DNA was isolated from colonies and assayed
for correct vector assembly by restriction digest, diag-
nostic PCR and/or DNA sequencing.Gibson assembly
Isothermal chew-back-anneal assembly, commonly known
as Gibson assembly, was carried out as described [17].
Briefly, vector and PCR product were prepared in the
same way as for yeast HR assembly. Fragments were com-
bined with either a home-made or commercially available
Gibson Assembly Master Mix. The home-made Master
Mix was prepared by combining 699 μL water, 320 μL of
5× isothermal reaction buffer (500 mM Tris-Cl, pH 7.5,
250 mg/mL PEG-8000, 50 mM MgCl2, 50 mM dithiothre-
itol, 1 mM each of four dNTPs, 5 mM NAD), 0.64 μL T5
Exonuclease (Epicentre, 10 U/μL), 20 μL Phusion DNA
polymerase (2 U/μL) and 160 μLTaq DNA ligase (40 U/μL).
This solution was divided into 20 μL aliquots and stored
at -20°C. Generally, >100 ng of linearized vector was added
to the mixture with an equal volume of PCR insert, generat-
ing a variable vector: insert ratio. The mixture was incu-
bated at 50°C for 1 hour and 0.5 μL was transformed into
E. coli as described above.Restriction/ligation cloning
Restriction/ligation cloning was carried out by standard
techniques. Ligations were incubated overnight at 16°C
and heat inactivated prior to transformation.Construction of attP-containing (pfYC3 series) plasmids
The 2 × attP fragment was PCR amplified from pLN-
ENR-GFP [18] with primers SG702/703. pfYC120:FL and
pfYC140:FL were digested with SalI and combined with
gel-purified PCR product in a Gibson assembly reaction
to obtain pfYC220:FL and pfYC240:FL, respectively. These
vectors were then digested with MluI and PmlI to release
the fragment containing the Rep20 and CEN/ARS ele-
ments. Approximately 100 ng of digested vector was then
combined in a Gibson assembly reaction containing 50
nM each SG814 and SG815 to recircularize the vector
while adding a unique PmeI site between the MluI and
PmlI sites. This yielded pfYC320:FL and pfYC340:FL. For
integration at the cg6 locus, these two vectors were co-
transfected with pINT [18] (~50 μg each) into P. falcip-
arum 3D7-attB (MRA-845 from MR4 [21]). Clonal popu-
lations were obtained by limiting dilution and integration
verified by PCR using the SG864/865 primer pair.
Construction of the pfcen5-1.5 mini-centromere
containing (pfYC4 series) plasmids
The pfcen5-1.5 element was amplified from P. falcip-
arum 3D7 genomic DNA with primers SG894/SG928.
pfYC102:FL and pfYC104:FL were digested with MluI
and PmlI and the gel-purified backbone lacking the
2×Rep20 element was attached to the SG894/SG928
PCR product by Gibson assembly to yield pfYC402:FL
and pfYC404:FL, respectively. Clones were verified by re-
striction digest and by sequencing with SG369.
Cloning Plasmodium falciparum ama1 and trxR genes into
pfYC120
The ama1 and trxR genes were amplified from P. falcip-
arum 3D7 genomic DNA using the AMA1 pcDT F/R
and Trx pcDT F/R primer pairs, respectively. Restric-
tion/ligation, Gibson assembly and yeast HR were per-
formed as described above.
Multi-cistronic constructs using the T2A for evaluating
subcellular trafficking rules
After Western blot and microscopic imaging analysis,
the identity of each strain was re-verified by PCR ampli-
fying and sequencing a uniquely identifying fragment of
the transfected construct using the SG763/764 and
SG502/646 primer pairs, respectively.
Parasite culture and transfection
Plasmodium falciparum strain 3D7 parasites were cul-
tured under 5% O2 and 5% CO2 in RPMI-1640 media
supplemented with 5 g/L Albumax II (Life Technolo-
gies), 2 g/L NaHCO3, 25 mM HEPES-K pH 7.4, 1 mM
hypoxanthine and 50 mg/L gentamicin. Transfections
used ~50 μg of each plasmid and were performed by the
spontaneous DNA uptake method [24] or by direct
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parasites were selected with 2.5 mg/L Blasticidin S,
1.5 μM DSM-1, 5 nM WR9920 (Jacobus Pharmaceuti-
cals) and/or 250 mg/L G-418 beginning 2-4 days after
transfection.
Monitoring transfection progress by luciferase expression
Firefly and Renilla luciferase levels were measured every
fourth day after transfection using the Dual-Luciferase
Reporter Assay System (Promega). Samples for measure-
ment were prepared by centrifugation of 1.25 mL of para-
site culture at 2% haematocrit to generate an ~25 μL
parasite-infected RBC pellet. Pellets were either used
immediately or stored at -80°C until needed for luciferase
measurements.
Parasite DNA extraction and qPCR analysis
DNA was harvested from schizont stage parasites at ≥
5% parasitaemia. Infected red blood cells (RBCs) were
treated with 0.1 mg/mL saponin in PBS to release para-
sites, which were either immediately used or stored in
liquid nitrogen for later analysis. Parasites were lysed for
1 hour at 50°C in 200 μL of 50 mM Tris-Cl pH 8.0,
50 mM EDTA, 0.5 mg/mL SDS and 10 μL of protease
solution (Qiagen). After adding RNase A (28 U; Qiagen),
reactions were incubated at 37°C for 5 min. After adding
20 μL of 6 M sodium perchlorate, DNA was isolated by
phenol/chloroform extraction and ethanol precipitation.
qPCR reactions (20 μL each) contained 1× Thermopol
Buffer, 0.2 mM dNTPs, 200 nM relevant primer pair
(Additional file 2), 0.5× SYBR Green I (Life Technolo-
gies), 0.1 μL Taq DNA polymerase and 5 μL of a DNA
dilution. Thermocycling was performed on a Roche
LightCycler 480 II for 40 cycles according to the follow-
ing programme: 95°C for 20 sec; denature: 95°C for
3 sec; anneal/extend: 60°C for 30 sec; fluorescence meas-
urement. Vector-borne amplicons (drug resistance
marker genes) and a native chromosomal locus (β-actin)
were quantified by comparison with plasmid or PCR-
amplified DNA standards, respectively.
Western blot
Approximately 106 late-stage parasites were harvested by
lysis of infected RBCs with 0.5 g/L saponin and then
lysed by heating in urea sample buffer (40 mM dithio-
threitol, 6.4 M urea, 80 mM glycylglycine, 16 g/L SDS,
40 mM Tris-Cl, pH 6.8) at 95°C for 10 min. After separ-
ation by SDS-PAGE, proteins were transferred to a
PVDF membrane and probed with an antibody against
firefly luciferase (FL) (Promega G7451), neomycin phos-
photransferase II (Millipore 06-747) or green fluorescent
protein (Abcam ab1218). Blots were then imaged using a
horseradish peroxidase-coupled secondary antibody and
SuperSignal West Femto substrate (Thermo Scientific).Northern blot
Total RNA was purified from infected RBCs with a com-
bination of Tri Reagent RT Blood (Molecular Research
Center) and an RNeasy Mini Kit (Qiagen). One mL of
parasite culture at 20% haematocrit and ~10% late-stage
parasitaemia was frozen on liquid nitrogen and thawed
with the addition of 3 mL Tri Reagent RT Blood. After
phase separation with 0.2 mL BAN (Molecular Research
Center), 2 mL of the upper aqueous phase was mixed
with 2 mL ethanol and applied to an RNeasy Mini col-
umn for purification according to the manufacturer’s in-
structions. Total RNA (6.5 μg) for each sample (with or
without the addition of 6 pg FL RNA generated by in vi-
tro transcription) was mixed with an equal volume of
denaturing sample buffer (95% formamide, 0.25 g/L
SDS, 0.25 g/L bromophenol blue, 0.25 g/L xylene cya-
nol, 2.5 g/L ethidium bromide, 50 mM EDTA) and
heated at 75°C for 10 min before loading on a 1% TAE
agarose gel. Electrophoresis was performed at 80 V for
75 min and RNA was transferred to a Nylon membrane
(Pall Biodyne Plus) by downward capillary transfer in
50 mM NaOH for 90 min. After UV fixation (Stratagene
Stratalinker, 1.25 mJ), the membrane was probed and
imaged with the North2South Chemiluminescent De-
tection Kit (Thermo). The biotinylated FL probe was
prepared from a DNA template generated by PCR with
primers SG311 and SG313.
Fluorescence microscopy
For live cell imaging, parasite cultures were incubated
for 20 min with 30 nM MitoTracker Deep Red FM (Life
Technologies). Infected RBCs were then washed with
phosphate-buffered saline and applied to poly-L-lysine
-coated glass-bottom culture dishes (MatTek, Ashland,
MA, USA). Attached cells were overlaid with RPMI
media (free of phenol red and Albumax II) containing
2 μg/mL Hoechst 33342 (Sigma), and imaged immedi-
ately at room temperature using a Nikon Ti-E inverted
microscope with a 100× objective and a Photometrics
CoolSNAP HQ2 CCD camera. Images were collected
with the Nikon NIS Elements software and processed
using ImageJ [26].
Results
Vector family design and features
In creating this plasmid vector resource several useful de-
sign criteria have been incorporated, namely: (1) access to
multiple, orthogonal and high-fidelity strategies for clon-
ing a target fragment into the identical context; (2) pre-
installed utility features including access to all commonly
used P. falciparum selection markers (bsd1, hdhfr, ydhodh
and nptII), plasmid integration sequences (attP sites) [18],
and plasmid segregation/maintenance features such as
Rep20 [19] and the mini-centromere, pfcen5-1.5 [20];
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ing for user-specific needs; and, (4) ease of manipulation
using reagents that are readily prepared in-house or com-
mercially available at low cost.
This vector family framework includes access to
yeast homologous recombination (HR) [16], Gibson as-
sembly [17] and restriction/ligation as central cloning
strategies (Figure 1). The challenges associated with
the traditionally used restriction/ligation method when
cloning P. falciparum sequences have been described
[13]. It is thought that the observed genomic deletions
and re-arrangements are related to the long (A + T)-
rich regions in combination with the restriction and
ligation process and the instability of these constructs
in E. coli. Though inefficient overall, this strategy is
used successfully, and so it is preserved as an option
that interfaces directly with the more efficient yeast
HR and Gibson strategies.
A major advantage of both Gibson and yeast HR strat-
egies over traditional restriction ligation based cloning is
that they do not require enzymatic digestion of the
inserted fragment, which can impose constraints on
cloning target DNA that contains these restriction sites
internally. Rather, as they depend on homologous ends
overlapping with a digested vector, the insert does not
need to be digested. This allows greater flexibility by











Figure 1 Schematic of the homology-based (yeast HR and
Gibson assembly) and traditional restriction/ligation cloning
strategies selected as part of an integrated framework for the
orthogonal assembly of Plasmodium falciparum constructs.
Beginning with a common primer set, PCR products and the desired
vector backbone (see Figure 2 for details), the identical target
plasmid can be assembled using any of these approaches
individually or in parallel.to be used. Yeast HR requires more overall time com-
pared to Gibson and restriction/ligation cloning, as
S. cerevisiae grows more slowly than E. coli. However,
this strategy efficiently yields target constructs and all
the key components can be inexpensively generated in-
house [23]. The Gateway® strategy (Life Technologies)
has also been used to construct P. falciparum vectors
[27]. This approach has not been included in the current
study, as it is significantly more expensive than the
methods described here. However, when needed, the fea-
tures required for enabling Gateway® cloning should be
straightforward to introduce into the framework de-
scribed below.
The overall architecture of this new vector family and
the built-in utility features are summarized in Figure 2,
and is derived from the pfGNr plasmid previously depos-
ited as MRA-462 in MR4. This plasmid contains bacterial
(pMB1) and yeast (CEN6/ARS4) origins of replication,
and the kanMX4 gene under the control of a hybrid bac-
terial/yeast promoter to facilitate selection of bacterial or
yeast colonies on kanamycin or G-418, respectively. This
plasmid contains two P. falciparum gene expression cas-
settes consisting of the commonly used 5′/3′UTR pairs
PfCaM/Pfhsp86 and PcDT/PfHRPII arranged head-to-head
to improve transcriptional efficiency [28]. In P. falciparum,
plasmid selection using G-418 is enabled by a gfp-nptII
gene fusion expressed from the PcDT/PfHRPII cassette,
and a 2×Rep20 element to enhance plasmid segregation
during replication is also present [19].
From this vector, a library of eight base plasmids was
first created in which each of the four frequently used
P. falciparum selection markers was cloned into one of
the two P. falciparum expression cassettes. For ease of
reference, a nomenclature to describe the various vector
family members was defined. Plasmids are designated as
pfYCxAB, where x is a series number indicating the pres-
ence of a specific set of utility features (1 = Rep20/yCEN,
2 = Rep20/yCEN/2×attP, 3 = 2 × attP and 4 = pfcen5-1.5)
and A and B denote the resistance marker expressed from
the PfCaM/PfHsp86 (cassette A) and PcDT/PfHRPII (cas-
sette B) UTR pairs, respectively (0 = no marker; 1 = nptII;
2 = bsd; 3 = hdhfr; and 4 = ydhodh). Introducing the 2 × attP
site, which facilitates site-specific integration mediated by
the Bxb1 integrase into compatible attB strains [18], at the
SalI site yields the pfYC2 plasmid series. Two representative
members, namely pfYC220:FL and pfYC240:FL (Additional
file 3), were generated in this study and provide a standard-
ized approach for easily generating the entire set. Both the
pfYC1 and pfYC2 plasmids facilitate manipulation through
yeast homologous recombination, Gibson assembly and
traditional restriction/ligation cloning to provide the great-
est flexibility in assembling a specific construct.
A limited set of pfYC3 (pfYC320:FL and pfYC340:FL)





































Figure 2 Schematic summary of the new family of plasmid vectors. Plasmids are designated by the pfYC prefix, a series number (1-4) and a
number (0-4) defining the resistance marker present in expression cassette A (5′PfCaM/3′PfHsp86 UTRs) or B (5′-PcDT/3′PfHRPII UTRs). The series
number is defined by specific utility features included in the plasmid as follows: 1 = yeast CEN/ARS origin to enable plasmid maintenance in S.
cerevisiae during yeast HR and a 2 × Rep20 element to improve plasmid segregation in P. falciparum [19]; 2 = same as in 1, but with a 2 × attP
element added to enable site-specific chromosomal integration into existing attB+ strains [18]; 3 = 2 × attP element is present, but the yeast CEN/
ARS origin and 2 × Rep20 elements have been eliminated; and 4 = the pfcen5-1.5 mini-centromere element is included to facilitate plasmid
segregation and maintenance at single copy in P. falciparum [20], while the yeast origin, 2 × Rep20 and 2 × attP elements have been eliminated.
P. falciparum resistance markers are designated as: 0 = none; 1 = nptII (G-418 resistance); 2 = bsd (Blasticidin S resistance); 3 = hdhfr (WR99210
resistance); and 4 = ydhodh (DSM-1 resistance). A non-resistance gene cloned into the available expression cassette is indicated by a colon
followed by the gene name (e g, pfYC110:FL indicates that the nptII and firefly luciferase genes are present in expression cassettes A and B,
respectively). Three HindIII sites present on the base plasmid are noted, as they are useful for topologically mapping these vectors and derivatives
to screen for potential rearrangements and large insertions or deletions.
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from the pfYC2 plasmid series. Elimination of the
Rep20 and CEN6/ARS4 elements from plasmids
intended for integration into the P. falciparum genome
may be desirable, as the Rep20 element has the poten-
tial to induce transcriptional silencing in a subtelomeric
chromosomal context [29]. Likewise, the S. cerevisiae-
derived CEN6/ARS4 element could possibly behave ab-
errantly when integrated into a P. falciparum chromo-
some. A limited set of pfYC4 plasmids (pfYC402:FL
and pfYC404:FL) has been made in which the Rep20
and CEN6/ARS4 elements in the pfYC1 series have
been replaced by the mini-centromere pfcen5-1.5. The
option to use yeast homologous recombination in the
pfYC3 and pfYC4 series is eliminated. However, Gibson
assembly and/or traditional restriction/ligation can be
used to generate final constructs that are immediately
ready for integration. Validated procedures for generat-
ing the complete set as dictated by user needs have also
been provided.Vector construction using various cloning methods
Several vectors were constructed to illustrate the ability
to successfully clone firefly and Renilla luciferase re-
porter genes, and two native P. falciparum genes (ama1
and trxR both ~1.85 kb and ~70% in (A + T) content)
into this vector family using all three cloning strategies.
Using yeast HR or Gibson assembly, firefly or Renilla lu-
ciferase was cloned into the available expression cassette
of the entire pfYC1 series (Additional file 3). All vectors
were sequenced and topologically mapped by HindIII re-
striction digestion. As shown in Figure 3A, final plas-
mids with the expected topology can be assembled using
these methods. Similarly, the candidate P. falciparum
genes ama1 and trxR were inserted into pfYC120 using
the three vector assembly methods in parallel. Cloning
reactions were carried out using the same insert and
vector preparations to minimize differences between the
materials used in each reaction. Five colonies derived
from each cloning method were screened for each gene
target and mapped by HindIII digestion to establish
pfYC120
M - FL + FL
pfYC140
M - FL + FL
pfYC102
M - FL + FL
pfYC104
M - FL + FL
pfYC110















































































Figure 3 Heterologous and native Plasmodium falciparum genes can be successfully assembled into pfYC vectors using all three
cloning strategies. (A) The firefly luciferase gene (FL = 1.65 kb) was cloned into the pfYC1 and pfYC3 series (Additional file 3) using either yeast
HR or Gibson assembly. Topological mapping with HindIII digestion yields three fragments, as FL and the selection markers do not contain HindIII
sites. A 3.9 kb fragment is released from the pfYC1 series whether FL is present or not (Figure 2). The fragments containing cassettes A and B
from pfYC10x:FL plasmids are (1.5 kb + FL) = 3.2 kb and (1.7 + selection marker size) kb, respectively. Similarly, the fragments containing cassettes A
and B from pfYC1x0:FL plasmids are (1.5 + selection marker size) kb and (1.7 + FL size) = 3.4 kb, respectively. The sizes of the different selection
markers are: nptII (0.8 kb); hdhfr (0.6 kb); bsd (0.4 kb) and ydhodh (0.95 kb). (B) Two native P. falciparum genes, ama1 (apical membrane antigen 1;
PF3D7_1133400; 1.87 kb) and trxR (thioredoxin reductase; PF3D7_0923800.1; 1.85 kb) were cloned in parallel using restriction/ligation, Gibson
assembly and yeast HR, and the same PCR products and digested pfYC120 vector. Successful gene insertion is expected to yield three HindIII
digestion products that include: a backbone fragment (denoted as C); cassette B with the ama1 or trxR gene inserted (denoted as B when no
insert is present and B′ when containing the proper insert); and cassette A containing the bsd gene (denoted as A). As a reference, the parent
pfYC120 plasmid yields products denoted as A, C and B upon HindIII digestion. The asterisk in the yeast HR trxR panel denotes sample
degradation that occurred during storage prior to analysis by gel electrophoresis.
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assembly yielded topologically correct plasmids for both
gene targets. However, under the conditions tested,
yeast HR and restriction/ligation yielded the expected
plasmid for trxR only. Overall, these data show that all
three methods can be used to successfully clone native
P. falciparum genes into this new vector family. Import-
antly, these independent cloning strategies allow use of
the same plasmid backbone and insert combinations to
assemble the identical final construct, thus improving
the flexibility and overall ease with which P. falciparum
vectors are made.
Plasmids in this vector family can be maintained as stable
episomes and chromosomally integrated in Plasmodium
falciparum
Toward establishing this vector family as a verified re-
source and a framework for routine use in P. falciparum
transgenic experiments, their ability to yield stable epi-
somal and integrated P. falciparum lines was evaluated.The entire pfYC1AB:FL vector set was transfected either
singly or in a paired combination (pfYC110/pfYC120)
into P. falciparum strain 3D7. Transfected parasites were
selected using the appropriate drug(s), and growth was
monitored by following luciferase activity. As shown in
Figure 4A, parasites transfected with these plasmids
were successfully selected with typical kinetics [30,31].
Interestingly, under the conditions tested, the pfYC104:
FL- and pfYC140:FL- transfected parasites selected with
DSM-1 emerged more rapidly than parasites selected
with Blasticidin S, WR99210 or G-418. Dual plasmid
transfected parasites emerged at rates similar to those
observed in single plasmid transfections (Figure 4B).
Copy numbers for the various pfYC1 plasmids were also
determined by quantitative PCR using the single-copy
chromosomal β-actin gene as a reference. These data in-
dicate that plasmids selected with Blasticidin S, DSM-1
and G-418 are maintained at an average ≤ five copies,
and for WR99210 at ~ ten copies per parasite genome
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Figure 4 The pfYC plasmid family exhibits typical behaviour during Plasmodium falciparum transfection, and can be maintained
episomally and chromosomally integrated. (A and B) The entire pfYC1xx:FL plasmid series was either transfected individually (A) or as a single
pair (pfYC110:FL + pfYC120:RL) (B) under the appropriate drug selection initiated on day 4 post-transfection (arrow). Firefly and Renilla luciferase
levels were monitored to assess parasite population growth kinetics until a parasitaemia ≥1% was attained. (C). The copy number of each
plasmid per parasite genome was determined for both the single and double transfections. (D) PCR confirmation of chromosomal integration of
pfYC320 and pfYC340 at the cg6 locus in the P. falciparum 3D7-attB strain. The β-actin gene was PCR amplified as a positive control.
Wagner et al. Malaria Journal 2013, 12:373 Page 8 of 13
http://www.malariajournal.com/content/12/1/373P. falciparum vectors [7,20], indicating that the pfYC
vector family behaves similarly to currently used plas-
mids and is suitable for use in transgenic experiments.
Frequently, the ability to site-specifically integrate con-
structs is preferred to ensure stable, homogeneous trans-
gene expression at single copy. The pfYC3 plasmid
series is designed to accomplish this by combining clon-
ing strategy flexibility and a site-specific integration attP
utility feature [18], while eliminating plasmid elements
that are potentially deleterious when chromosomally in-
tegrated (Rep20 and CEN6/ARS4). As validation of this
desired behaviour, 3D7-attB parasites were transfected
with pfYC320:FL and pfYC340:FL. Stable parasite lines
expressing FL were selected under Blasticidin S or DSM-
1 pressure, respectively, and site-specific integration at
the cg6 locus was detected by PCR both at the popula-
tion level and in isolated clones (Figure 4D). Overall,
these data collectively show that the pfYC vector family
provides a robust and complementary set of high effi-
ciency and timesaving cloning strategies for enablingroutine assembly of DNA constructs that can be suc-
cessfully used in P. falciparum transgenic experiments.
Of note, while we have assembled two representative
pfYC4 series plasmids containing the pfcen5-1.5 centro-
mere element as a useful starting point for future use,
we have not evaluated these in transfections.
Expanded transgene expression from a single plasmid
that is compatible with proper subcellular trafficking
The ability to simultaneously express multiple proteins
from a single plasmid irrespective of their subcellular
localization can be highly useful, as it reduces the need
for sequential transfections and limits exhausting the
small set of available selection markers. The virus-
derived 2A-like peptide sequences (2A tags), which have
been used successfully in mammalian, yeast, plant and
protozoan contexts to enable polycistronic expression
from a single eukaryotic mRNA [14,15] were used to ac-
complish this. These 2A tags mediate peptide bond
“skipping” between conserved glycine and proline
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extension encoded by the tag, and the other with an
N-terminal proline. The small size (eight conserved
amino acid positions) and broad cross-species function-
ality of the 2A tag makes it an attractive candidate for
application to P. falciparum, an organism in which this
technology has not been extensively explored. As an en-
tire expression cassette is usually committed exclusively
to expressing a selection marker, an initial experiment
was designed to address whether the Thosea asigna virus
2A-like sequence (T2A) could be used to expand the
number of genes expressed from this cassette without
compromising the ability to select transfected parasites.
T2A with a short, N-terminal linker region [32] was
inserted between the FL and nptII genes in cassette A to
generate pfYC101:FL-2A-nptII. A control construct con-
taining a non-functional tag (T2Am), in which two con-
served residues are mutated to alanine [32] was also
generated (Figure 5A). These plasmids were transfected
into P. falciparum 3D7 under G-418 selection press-
ure and obtained resistant parasites with FL activity
(Figure 5B), demonstrating the production of functional
nptII and FL proteins in both cases. The ability of T2A to
produce distinct FL and nptII proteins from a single
mRNA was confirmed by Western and Northern blot
(Figure 5C and 5D, respectively). As expected, mutating
T2A to T2Am eliminates the formation of discreteA
pSG93 FL T2A nptII





























Figure 5 The Thosea asigna virus 2A-like peptide (T2A) enables expre
single expression cassette. (A) Schematic of FL-nptII and control construc
(C) Western blot detection of FL- and nptII- containing proteins. (D) Northe
3D7 + FL indicates the inclusion of a synthetic FL mRNA produced by in vitproteins, but does not alter the size of the FL-nptII
mRNA. This initial characterization, in addition to dem-
onstrating T2A functionality in P. falciparum, highlights
the potential for using T2A to recover valuable expres-
sion capacity by encoding additional information into
existing selection marker cassettes while eliminating the
unpredictability of how a protein fusion will function.
Next, the flexibility with which T2A can be used to
produce dicistronic messages encoding proteins des-
tined for distinct subcellular compartments within the
parasite and its RBC host was examined. Several dicis-
tronic constructs encoding an N-terminal Venus yellow
fluorescent protein (vYFP) and a C-terminal tdTomato
protein (tdTom) separated by T2A were built in the
pfYC120 vector. Previously validated apicoplast, mito-
chondrial and RBC export targeting sequences derived,
respectively, from: acyl carrier protein (PF13_0208500;
aa 1-60 = ATS) [33], HSP60 (PF13_1015600; aa 1-68 =
MTS) [34], and knob-associated histidine-rich protein
(PF13_0202000; aa 1-69 = PEX) [35] were used. Seven
contexts were created in which a different protein tar-
geting signal (or none at all) was placed immediately
upstream of vYFP and/or tdTom as follows: (a) vYFP-
2A-tdTom; (b) vYFP-2A-ATS-tdTom; (c) vYFP-2A-
MTS-tdTom; (d) vYFP-2A-PEX-tdTom; (e) MTS-vYFP-
2A-MTS-tdTom; (f ) PEX-vYFP-2A-PEX-tdTom; and,
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and production of vYFP versus a possible fusion to
tdTom was distinguished by Western blot (Figure 6).
Overall, when no targeting sequence was upstream of
vYFP, the downstream tdTom was faithfully trafficked
to the subcellular compartment based on the associated
targeting sequence. Similarly, when vYFP and tdTom
are associated with the same targeting sequence (para-
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Figure 6 The 2A sequence can be used to successfully and predictab
targeting sequences were N-terminally fused to an upstream vYFP and a d
proteins were localized using direct fluorescence microscopy imaging. Mito
33342. Legend: ATS = apicoplast targeting sequence; MTS =mitochondrial tboth were trafficked as separate proteins to the same
subcellular compartment, as expected. For the ATS-
vYFP-2A-tdTom construct, vYFP was trafficked to the
apicoplast as expected. Interestingly, a substantial frac-
tion of the tdTom was mislocalized to the apicoplast
with some signal distributed in the parasite’s cytoplasm.
By Western blot, vYFP was detected as both the iso-
lated protein and the tdTom fusion (~ 100 kDa). Pre-
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ownstream tdTom reporter separated by T2A. The vYFP and tdTom
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argeting sequence and PEX = protein export element.
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arose due to the expected T2A behaviour. These data
suggest that ‘ribosome skipping’ might be less efficient
and/or the downstream protein is more often misdirected
when the upstream protein is apicoplast-targeted, at least
within the context tested by the present constructs. This
outcome is reminiscent of “slipstreaming” observed when
using T2A for multi-cistronic expression of secreted pro-
teins in mammalian cells, though this phenomenon is
thought to be primarily influenced by the C-terminal por-
tion of the upstream protein [36], which does not vary
across the constructs used here. However, since the
vYFP-2A-ATS-tdTom construct exhibited the expected
subcellular targeting patterns, and given the other combi-
nations in which proper subcellular trafficking was ob-
served, some rules for using T2A to successfully achieve
multi-cistronic protein expression with proper subcellular
targeting have been defined.
Discussion
A validated set of broadly useful plasmid vectors has been
developed that enables versatile assembly of P. falciparum
constructs, a frequently time-consuming process given
the (A + T)-richness and large size of final vectors. This
has been achieved by integrating simultaneous access to
the high efficiency and inexpensively available yeast hom-
ologous recombination, Gibson assembly and conven-
tional restriction/ligation cloning strategies. All three
strategies are technically straightforward and use the
same restriction enzyme-digested vector and PCR prod-
ucts generated with the same primer set. In principle, all
three strategies can be executed in parallel or used inter-
changeably without the need for new genetic reagents,
and can be used to successfully clone both reporter and
native P. falciparum genes. Additionally, several widely
used utility features for enhancing plasmid segregation
and site-specific chromosomal integration have been pre-
installed, and validated operations to enable user-tailored
modifications to this vector family are provided.
In addition to improving the ease of constructing new
P. falciparum expression vectors, a strategy for increas-
ing the amount of expressible information that can be
encoded on a single plasmid using a minimal set of
5′/3′-UTR cassettes was also developed. From a tech-
nical standpoint, this is especially useful as it simplifies
the vector construction process by reducing overall plas-
mid size and instability during propagation in E. coli.
Practically, this provides more efficient avenues for ad-
dressing questions in parasite biology requiring the co-
expression of multiple genes. For example, several anti-
genically variant, multi-gene families, such as PfEMP1,
STEVORs and RIFINs, are combinatorially expressed by
the parasite to modulate host-parasite interactions, such
as immune recognition and evasion [37,38]. Therefore,the ability to achieve pre-determined expression of spe-
cific combinations of these proteins could prove useful
in understanding their combined contributions to these
outcomes. Furthermore, subsets of proteins involved in
multi-gene pathways must often be trafficked to distinct
subcellular compartments. The tricarboxylic acid cycle
[39,40], lipid and isoprenoid biosynthesis [41] and haem
biosynthesis [42] involve multiple proteins distributed
between the cytosol, mitochondrion and apicoplast, or
exclusively targeted to one of these organelles. Also, a
substantial fraction of the parasite-encoded proteome is
trafficked to the host RBC, including the antigenically
variant STEVOR and RIFIN families, and a significant
number of these trafficked proteins play essential but
poorly understood roles [43]. Therefore, strategies for
achieving multi-cistronic expression while simultan-
eously preserving faithful protein trafficking will be
broadly useful for studying parasite biology. Altogether,
these openly available tools and validated methods
should provide a convenient option for routinely gener-
ating P. falciparum plasmid vectors.
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